Search
Setmelanotide
go.drugbank.com/drugs/DB11700ApprovedInvestigational[A224449] Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. … [L24429] On May 4, 2023, it was approved by Health Canada.[L46327]
Tafenoquine
go.drugbank.com/drugs/DB06608ApprovedInvestigational[A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria.
Belzutifan
go.drugbank.com/drugs/DB15463ApprovedInvestigationalby Merck in 2019). … [L35995] The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers.
Afamelanotide
go.drugbank.com/drugs/DB04931Approved[L9086] It differs structurally from its endogenous counterpart by only two amino acids - these structural differences improve biological efficacy by imparting a greater affinity for its target and a longer
Remestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawn[L11022] Remestemcel-L was later approved by the FDA on December 18, 2024. … of the recipients [A31818]. aGvHD is often characterized by the presence of inflammatory cascades through signalling of activated T cells.
Glasdegib
go.drugbank.com/drugs/DB11978ApprovedInvestigational[A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). … [L11935] Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade.
Omeprazole
go.drugbank.com/drugs/DB00338ApprovedInvestigationalVet approvedOriginally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. … These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid.
Products: OMEP 10MG, OMEP 20MGTebipenem pivoxil
go.drugbank.com/drugs/DB16840Approved[L57979,L57980] It retains activity against many extended-spectrum beta-lactamase producers but not against organisms producing serine or metallo-carbapenemases. … [L57979] Carbapenems are the standard treatment for severe or resistant Gram-negative infections but had until now been available only intravenously, meaning patients with resistant complicated urinary
Vildagliptin
go.drugbank.com/drugs/DB04876ApprovedInvestigational[A232488] By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are incretin hormones that promote … [A232488] Oral vildagliptin was approved by the European Medicines Agency in 2008 for the treatment of type II diabetes mellitus in adults as monotherapy or in combination with [metformin], a sulfonylurea
Mixtures: GALVUS MET (50MG/500 MG), Galvus Met Tablet 50mg/500mgProducts: Galvus Tablet 50mg, Alvilda 50mg TabletsTradipitant
go.drugbank.com/drugs/DB12580ApprovedInvestigational[A275353] Approved by the FDA on December 30, 2025, tradipitant is indicated for the prevention of vomiting induced by motion.